Name | NL-1 |
Description | NL-1, a mitoNEET inhibitor, exhibits antileukemic effects. |
Cell Research | Cell Line:REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines. Concentration:10 μM, 20 μM, 30 μM, 40 μM, 50 μM, 60 μM, 70 μM, 80 μM, 100 μM.Incubation Time:72 hours |
Animal Research | Animal Model:10 female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (6-8 month old) injected with TOM-1 ALL cells. Dosage:10 mg/kg.Administration:Intraperitoneal injection; daily; for 5 days |
In vitro | NL-1 Reduced the number of viable cells in REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines, in a concentration-dependent manner. |
In vivo | NL-1 showed antileukemic activity in an in vivo mouse ALL model |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 250 mg/mL (745.25 mM), Sonication is recommended.
|
Keywords | Inhibitor | viability | Mitochondrial Metabolism | leukemia | CISD1 | antileukemic | MitoNEET | NL 1 | lymphoblastic | NL-1 | inhibit | B-Cell | Autophagy | acute | anti-cancer | NL1 |
Inhibitors Related | Stavudine | Xylitol | Myricetin | Sodium 4-phenylbutyrate | Hydroxychloroquine | Guanidine hydrochloride | Taurine | Curcumin | Oxyresveratrol | Paeonol | Naringin | Gefitinib |
Related Compound Libraries | Reprogramming Compound Library | Bioactive Compound Library | Autophagy Compound Library | Inhibitor Library | Mitochondria-Targeted Compound Library | NO PAINS Compound Library | Metabolism Compound Library | Lipid Metabolism Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |